Cosentyx FDA Approval History
Last updated by Judith Stewart, BPharm on June 30, 2022.
FDA Approved: Yes (First approved January 21, 2015)
Brand name: Cosentyx
Generic name: secukinumab
Dosage form: Injection
Company: Novartis Pharmaceuticals Corporation
Treatment for: Plaque Psoriasis, Ankylosing Spondylitis, Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, Enthesitis-Related Arthritis
Cosentyx (secukinumab) is a selective interleukin-17A (IL-17A) inhibitor for the treatment of plaque psoriasis, ankylosing spondylitis, psoriatic arthritis, non-radiographic axial spondyloarthritis, and enthesitis-related arthritis.
- Cosentyx is indicated for the treatment of:
- moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy
- active psoriatic arthritis (PsA) in patients 2 years of age and older
- adults with active ankylosing spondylitis (AS)
- adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation
- active enthesitis-related arthritis (ERA) in patients 4 years of age and older.
Development timeline for Cosentyx
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.